JP2004532229A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532229A5 JP2004532229A5 JP2002584915A JP2002584915A JP2004532229A5 JP 2004532229 A5 JP2004532229 A5 JP 2004532229A5 JP 2002584915 A JP2002584915 A JP 2002584915A JP 2002584915 A JP2002584915 A JP 2002584915A JP 2004532229 A5 JP2004532229 A5 JP 2004532229A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazol
- diphenyl
- carbamic acid
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 40
- -1 N-pyridyl Chemical group 0.000 claims 28
- 125000002947 alkylene group Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NSWZAERQBNOYAM-UHFFFAOYSA-N (2,4-difluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(F)C=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NSWZAERQBNOYAM-UHFFFAOYSA-N 0.000 claims 4
- LHAHTHILLRCRBM-UHFFFAOYSA-N (2-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LHAHTHILLRCRBM-UHFFFAOYSA-N 0.000 claims 4
- LXGNTFODLNMYKQ-UHFFFAOYSA-N (2-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptan-2-yl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LXGNTFODLNMYKQ-UHFFFAOYSA-N 0.000 claims 4
- KVVFDLOMTIYNNM-UHFFFAOYSA-N (2-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 KVVFDLOMTIYNNM-UHFFFAOYSA-N 0.000 claims 4
- IBVGJCKUNHQTJG-UHFFFAOYSA-N (2-methylphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 IBVGJCKUNHQTJG-UHFFFAOYSA-N 0.000 claims 4
- DNURSCPDSPXAJU-UHFFFAOYSA-N (3,4-difluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(F)C(F)=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DNURSCPDSPXAJU-UHFFFAOYSA-N 0.000 claims 4
- XJAKUYMMKREWNM-UHFFFAOYSA-N (4-chlorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(Cl)C=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 XJAKUYMMKREWNM-UHFFFAOYSA-N 0.000 claims 4
- WJLTUBGHNUKNRQ-UHFFFAOYSA-N (4-chlorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(Cl)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WJLTUBGHNUKNRQ-UHFFFAOYSA-N 0.000 claims 4
- WCFPXERLDSROKC-UHFFFAOYSA-N (4-cyanophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(C#N)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WCFPXERLDSROKC-UHFFFAOYSA-N 0.000 claims 4
- CSFBUGVVQNTZGS-UHFFFAOYSA-N (4-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(F)C=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CSFBUGVVQNTZGS-UHFFFAOYSA-N 0.000 claims 4
- UWKODOYNVJUKMA-UHFFFAOYSA-N phenyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UWKODOYNVJUKMA-UHFFFAOYSA-N 0.000 claims 4
- QMIKRYNXYTZTKA-UHFFFAOYSA-N (2,4-difluorophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=C(F)C=C(F)C=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QMIKRYNXYTZTKA-UHFFFAOYSA-N 0.000 claims 3
- ZFCUKLAHWGJHDA-UHFFFAOYSA-N (2,4-difluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(F)C=C(F)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 ZFCUKLAHWGJHDA-UHFFFAOYSA-N 0.000 claims 3
- FTFMPYWXZDLNAM-UHFFFAOYSA-N (2,6-difluorophenyl) n-[6-[4,5-bis(4-fluorophenyl)-2-methylimidazol-1-yl]hexyl]carbamate Chemical compound FC=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 FTFMPYWXZDLNAM-UHFFFAOYSA-N 0.000 claims 3
- BWPRPBUIQPVVFD-UHFFFAOYSA-N (2-fluorophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BWPRPBUIQPVVFD-UHFFFAOYSA-N 0.000 claims 3
- FROPPAHABGJTLA-UHFFFAOYSA-N (2-fluorophenyl) n-[6-[4,5-bis(4-fluorophenyl)-2-methylimidazol-1-yl]hexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 FROPPAHABGJTLA-UHFFFAOYSA-N 0.000 claims 3
- IUNZJOWJONPLGO-UHFFFAOYSA-N (2-methoxyphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C IUNZJOWJONPLGO-UHFFFAOYSA-N 0.000 claims 3
- NBASSYYNACEAGJ-UHFFFAOYSA-N (2-methylphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NBASSYYNACEAGJ-UHFFFAOYSA-N 0.000 claims 3
- UGSXGFMGLUGUAU-UHFFFAOYSA-N (4-chlorophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=C(Cl)C=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UGSXGFMGLUGUAU-UHFFFAOYSA-N 0.000 claims 3
- JQCVZSZSAVHKDK-UHFFFAOYSA-N (4-cyanophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=C(C#N)C=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JQCVZSZSAVHKDK-UHFFFAOYSA-N 0.000 claims 3
- LNRLTYJRJMLPES-UHFFFAOYSA-N (4-cyanophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=C(C#N)C=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LNRLTYJRJMLPES-UHFFFAOYSA-N 0.000 claims 3
- LJVAEURIXMPCHM-UHFFFAOYSA-N (4-fluorophenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=C(F)C=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LJVAEURIXMPCHM-UHFFFAOYSA-N 0.000 claims 3
- YEYYSMBWLXKXSJ-UHFFFAOYSA-N (4-fluorophenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C=1C=C(F)C=CC=1OC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YEYYSMBWLXKXSJ-UHFFFAOYSA-N 0.000 claims 3
- ZCXQKBFXBDHCMV-UHFFFAOYSA-N (4-methoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C ZCXQKBFXBDHCMV-UHFFFAOYSA-N 0.000 claims 3
- ABKJPGCDYPXWKQ-UHFFFAOYSA-N (4-methoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C ABKJPGCDYPXWKQ-UHFFFAOYSA-N 0.000 claims 3
- VLPBIVLQDLAAMM-UHFFFAOYSA-N (4-methoxyphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NCCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C VLPBIVLQDLAAMM-UHFFFAOYSA-N 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 claims 3
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 claims 3
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims 3
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- VJHMAYPKFOEEMF-UHFFFAOYSA-N ethyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound CCOC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VJHMAYPKFOEEMF-UHFFFAOYSA-N 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims 3
- VNIZFYRBACXAQP-UHFFFAOYSA-N phenyl n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VNIZFYRBACXAQP-UHFFFAOYSA-N 0.000 claims 3
- KCHOVCICRIAYSX-UHFFFAOYSA-N phenyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=CC=1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 KCHOVCICRIAYSX-UHFFFAOYSA-N 0.000 claims 3
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- AYBJAAXONTZTRT-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C AYBJAAXONTZTRT-UHFFFAOYSA-N 0.000 claims 2
- TXTYAAMKKBDEHL-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C TXTYAAMKKBDEHL-UHFFFAOYSA-N 0.000 claims 2
- VHHYCPSXRJPUPU-UHFFFAOYSA-N (2,6-dimethoxyphenyl) n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC1=CC=CC(OC)=C1OC(=O)NCCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C VHHYCPSXRJPUPU-UHFFFAOYSA-N 0.000 claims 2
- HMJCRVRGZFQOMD-UHFFFAOYSA-N (2-fluorophenyl) n-[2-methyl-8-(2-methyl-4,5-diphenylimidazol-1-yl)octan-3-yl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C(C)C)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HMJCRVRGZFQOMD-UHFFFAOYSA-N 0.000 claims 2
- LVGPJSBRMDHIRR-UHFFFAOYSA-N (2-fluorophenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)-1-phenylhexyl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(C=1C=CC=CC=1)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 LVGPJSBRMDHIRR-UHFFFAOYSA-N 0.000 claims 2
- BDZLAFXHYNNBSK-UHFFFAOYSA-N (2-fluorophenyl) n-[8-(2-methyl-4,5-diphenylimidazol-1-yl)octan-3-yl]carbamate Chemical compound C=1C=CC=C(F)C=1OC(=O)NC(CC)CCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 BDZLAFXHYNNBSK-UHFFFAOYSA-N 0.000 claims 2
- WUTDHSLCSCRJJE-UHFFFAOYSA-N (2-methoxyphenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NC(C=C1)=CC=C1OCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C WUTDHSLCSCRJJE-UHFFFAOYSA-N 0.000 claims 2
- FZGDFPYGTTVJHF-UHFFFAOYSA-N (2-methoxyphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C FZGDFPYGTTVJHF-UHFFFAOYSA-N 0.000 claims 2
- SDPQMYWYNNWTLU-UHFFFAOYSA-N (2-methoxyphenyl) n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC1=CC=CC=C1OC(=O)NCCCCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C SDPQMYWYNNWTLU-UHFFFAOYSA-N 0.000 claims 2
- UXFHDVNGNFTBIX-UHFFFAOYSA-N (2-methylphenyl) n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound C=1C=CC=C(C)C=1OC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 UXFHDVNGNFTBIX-UHFFFAOYSA-N 0.000 claims 2
- RFLKXRLXXACOCO-UHFFFAOYSA-N (3-chlorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=C(Cl)C=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RFLKXRLXXACOCO-UHFFFAOYSA-N 0.000 claims 2
- QLVDMDDQLWVPLM-UHFFFAOYSA-N (4-chlorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(Cl)=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 QLVDMDDQLWVPLM-UHFFFAOYSA-N 0.000 claims 2
- CTCPSLZBROEIJK-UHFFFAOYSA-N (4-methoxyphenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1OC(=O)NC(C=C1)=CC=C1OCCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C CTCPSLZBROEIJK-UHFFFAOYSA-N 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- VZSXUVQCPYUMAW-UHFFFAOYSA-N ethyl n-[5-(2-methyl-4,5-diphenylimidazol-1-yl)pentyl]carbamate Chemical compound CCOC(=O)NCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VZSXUVQCPYUMAW-UHFFFAOYSA-N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- CRYHRFPPPYGXLU-UHFFFAOYSA-N methyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound COC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CRYHRFPPPYGXLU-UHFFFAOYSA-N 0.000 claims 2
- OFSWZLPOOKDXDP-UHFFFAOYSA-N methyl n-[7-(2-methyl-4,5-diphenylimidazol-1-yl)heptyl]carbamate Chemical compound COC(=O)NCCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFSWZLPOOKDXDP-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HVBXMFCCTUBMJH-UHFFFAOYSA-N (2-fluorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C(=CC=CC=2)F)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 HVBXMFCCTUBMJH-UHFFFAOYSA-N 0.000 claims 1
- RUFUOXCZFVHSGF-UHFFFAOYSA-N (2-fluorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C(=CC=CC=2)F)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RUFUOXCZFVHSGF-UHFFFAOYSA-N 0.000 claims 1
- IDONYIIJPCLJKI-UHFFFAOYSA-N (3,4-difluorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=C(F)C(F)=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 IDONYIIJPCLJKI-UHFFFAOYSA-N 0.000 claims 1
- CYCGLDOPUFZCSV-UHFFFAOYSA-N (3,4-difluorophenyl) n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=C(F)C(F)=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 CYCGLDOPUFZCSV-UHFFFAOYSA-N 0.000 claims 1
- WOLFTIJTUYIRFQ-UHFFFAOYSA-N (4-chlorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(Cl)=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 WOLFTIJTUYIRFQ-UHFFFAOYSA-N 0.000 claims 1
- SHTWNZPEBIGSSW-UHFFFAOYSA-N (4-fluorophenyl) n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC(F)=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 SHTWNZPEBIGSSW-UHFFFAOYSA-N 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 206010001513 AIDS related complex Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000029808 Psychomotor disease Diseases 0.000 claims 1
- YWDYYCUYUHBNGL-UHFFFAOYSA-N benzyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 YWDYYCUYUHBNGL-UHFFFAOYSA-N 0.000 claims 1
- NGMMWUXERKZVJI-UHFFFAOYSA-N butan-2-yl n-[6-(2-ethyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CCC(C)OC(=O)NCCCCCCN1C(CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 NGMMWUXERKZVJI-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- JCUFQSXXINWVIU-UHFFFAOYSA-N cyclohexyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound C1CCCCC1OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JCUFQSXXINWVIU-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- WIHGSFJBAYXSNS-UHFFFAOYSA-N ethyl n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1OCCN1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N=C1C WIHGSFJBAYXSNS-UHFFFAOYSA-N 0.000 claims 1
- GSVJWQNGCOHAMM-UHFFFAOYSA-N ethyl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CCOC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 GSVJWQNGCOHAMM-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- RNYLSGGTAIRFDR-UHFFFAOYSA-N phenyl n-[4-[2-(2-methyl-4,5-diphenylimidazol-1-yl)ethoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC=CC=2)C=CC=1OCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 RNYLSGGTAIRFDR-UHFFFAOYSA-N 0.000 claims 1
- JKCXQDIHXXYILY-UHFFFAOYSA-N phenyl n-[4-[3-(2-methyl-4,5-diphenylimidazol-1-yl)propoxy]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC=CC=2)C=CC=1OCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 JKCXQDIHXXYILY-UHFFFAOYSA-N 0.000 claims 1
- DWNVRDYRAQCINB-UHFFFAOYSA-N propan-2-yl n-[6-(2-methyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CC(C)OC(=O)NCCCCCCN1C(C)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 DWNVRDYRAQCINB-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- VLTNNAFYFSVVGS-UHFFFAOYSA-N tert-butyl n-[6-(2-ethyl-4,5-diphenylimidazol-1-yl)hexyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN1C(CC)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 VLTNNAFYFSVVGS-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28682701P | 2001-04-27 | 2001-04-27 | |
| PCT/US2002/012853 WO2002087569A1 (en) | 2001-04-27 | 2002-04-23 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532229A JP2004532229A (ja) | 2004-10-21 |
| JP2004532229A5 true JP2004532229A5 (https=) | 2005-12-22 |
Family
ID=23100337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002584915A Pending JP2004532229A (ja) | 2001-04-27 | 2002-04-23 | 脂肪酸アミド加水分解酵素阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6562846B2 (https=) |
| EP (1) | EP1389107A4 (https=) |
| JP (1) | JP2004532229A (https=) |
| CA (1) | CA2445294A1 (https=) |
| IL (1) | IL158300A0 (https=) |
| MX (1) | MXPA03009850A (https=) |
| WO (1) | WO2002087569A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002311784B2 (en) * | 2001-03-29 | 2007-11-22 | Michael Davis | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning |
| US6949574B2 (en) * | 2002-02-08 | 2005-09-27 | Bristol-Myers Squibb Company | (Oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| EP1558591B1 (en) | 2002-10-07 | 2014-05-07 | The Regents of The University of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| FR2850377B1 (fr) * | 2003-01-23 | 2009-02-20 | Sanofi Synthelabo | Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| US20080103209A1 (en) * | 2004-04-23 | 2008-05-01 | The Regents Of The University Of California | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US20060084659A1 (en) * | 2004-10-19 | 2006-04-20 | Michael Davis | Augmentation of psychotherapy with cannabinoid reuptake inhibitors |
| TW200633990A (en) | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| AR055831A1 (es) | 2004-12-30 | 2007-09-12 | Janssen Pharmaceutica Nv | Pepirazinilureas y piperidinilureas como moduladores de hidrolasa de amida de acidos grasos |
| ES2357129T3 (es) * | 2005-04-13 | 2011-04-19 | Neuraxon Inc. | Compuestos indólicos sustituidos que tienen actividad inhibidora de nos. |
| WO2006116773A2 (en) * | 2005-04-28 | 2006-11-02 | The Regents Of The University Of California | Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders |
| JP2009527483A (ja) | 2006-02-17 | 2009-07-30 | ザ・スクリプス・リサーチ・インステイチユート | 脂肪酸アミドヒドロラーゼの調節因子としてのオキサゾールケトン |
| KR100753240B1 (ko) | 2006-03-10 | 2007-08-30 | 한국지질자원연구원 | 합금 나노분말의 제조방법 |
| CA2702468A1 (en) * | 2007-10-12 | 2009-04-23 | University Of Connecticut | Therapeutic applications of fatty acid amide hydrolase inhibitors |
| EP2062578A1 (en) * | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
| KR20100103799A (ko) | 2007-11-16 | 2010-09-28 | 네우렉슨 인코포레이티드 | 내장통을 치료하기 위한 인돌 화합물 및 방법 |
| CA2714743C (en) | 2008-02-19 | 2017-01-17 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US8207226B1 (en) | 2008-06-03 | 2012-06-26 | Alcon Research, Ltd. | Use of FAAH antagonists for treating dry eye and ocular pain |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| ES2626246T3 (es) | 2009-09-09 | 2017-07-24 | Sumitomo Dainippon Pharma Co., Ltd. | Derivado de 8-oxodihidropurina |
| US20120225097A1 (en) | 2009-11-12 | 2012-09-06 | Hawryluk Natalie A | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| DE102012018115A1 (de) | 2012-09-13 | 2014-03-13 | Matthias Lehr | Aryl-N-(arylalkyl)carbamate als Hemmstoffe der Fatty Acid Amide Hydrolase |
| EP2931291B1 (en) | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| DE102013016573A1 (de) | 2013-10-04 | 2015-04-09 | Matthias Lehr | 1-Tetrazolylpropan-2-one als Inhibitoren von cytosolischer Phospholipase A2 und Fatty Acid Amide Hydrolase, insbesondere geeignet zur topischen Anwendung |
| US10414721B1 (en) | 2018-06-04 | 2019-09-17 | University Of Bern | Inhibitor of endocannabinoid cellular reuptake |
| CN111269083B (zh) * | 2020-02-24 | 2023-08-25 | 珠海市柏瑞医药科技有限公司 | 一种格尔伯特酸的合成方法 |
| US11999703B1 (en) | 2023-10-25 | 2024-06-04 | King Faisal University | 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT91878B (pt) * | 1988-10-03 | 1995-05-31 | Glaxo Group Ltd | Processo para a preparacao de derivados do imidazole com propriedades hipocolesterolemicas e hipolipidemicas |
| KR100291112B1 (ko) * | 1992-02-11 | 2001-09-17 | 더 존스 홉킨스 유니버시티 | 코엔자임에이-독립성트랜스아실라제및혈소판활성화인자억제제 |
| US5700826A (en) * | 1995-06-07 | 1997-12-23 | Ontogen Corporation | 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance |
-
2002
- 2002-04-23 MX MXPA03009850A patent/MXPA03009850A/es active IP Right Grant
- 2002-04-23 US US10/128,480 patent/US6562846B2/en not_active Ceased
- 2002-04-23 JP JP2002584915A patent/JP2004532229A/ja active Pending
- 2002-04-23 WO PCT/US2002/012853 patent/WO2002087569A1/en not_active Ceased
- 2002-04-23 CA CA002445294A patent/CA2445294A1/en not_active Abandoned
- 2002-04-23 IL IL15830002A patent/IL158300A0/xx unknown
- 2002-04-23 EP EP02728952A patent/EP1389107A4/en not_active Withdrawn
-
2004
- 2004-07-01 US US10/883,195 patent/USRE39634E1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532229A5 (https=) | ||
| DE69333616T2 (de) | Imidazole derivate und ihre anwendung als cytokine inhibitore | |
| RU99122164A (ru) | Замещенные имидазолы полезные при лечении воспалительных заболеваний | |
| JP2004520292A5 (https=) | ||
| JP3217191B2 (ja) | ヘテロ芳香族化合物およびこれを含有する植物保護剤 | |
| RU2342383C2 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОЛ-4-ИЛЭТИНИЛПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНКСИОЛИТИКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ НАРУШЕНИЙ, ОПОСРЕДУЕМЫХ РЕЦЕПТОРОМ mGLuR5 | |
| JP2002534519A5 (https=) | ||
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| JP2004521924A5 (https=) | ||
| JP2004520324A5 (https=) | ||
| RU2010101212A (ru) | Бром-фенил замещенные тиазолилдигидропиримидины | |
| JPH0776564A (ja) | メトキシイミノ酢酸誘導体およびこれを有効成分とする農園芸用殺菌剤 | |
| JP2006515604A5 (https=) | ||
| RU2012122056A (ru) | Ингибиторы фермента диацилглицерин-о-ацилтрансферазы типа 1 | |
| JP2006507355A5 (https=) | ||
| JP2008520665A5 (https=) | ||
| JP2004507501A5 (https=) | ||
| JP2005511516A5 (https=) | ||
| JP2005505583A5 (https=) | ||
| JP2006516626A5 (https=) | ||
| JP2004524279A5 (https=) | ||
| JP2000302680A (ja) | 脳保護剤 | |
| JPH05213928A (ja) | ジヒドロピラン誘導体およびこれを含有する殺菌植物保護剤 | |
| JP2004517151A5 (https=) | ||
| JP2005526133A5 (https=) |